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Abstract
AIM
To investigate the neoadjuvant chemotherapy (NAC) 
effect on the survival of patients with proper stomach 
cancer submitted to D2 gastrectomy.
METHODS
We proceeded to a review of the literature with 
PubMed, Embase, ASCO and ESMO meeting abstracts 
as well as computerized use of the Cochrane Library 
for randomized controlled trials (RCTs) comparing NAC 
followed by surgery (NAC + S) with surgery alone (SA) 
for gastric cancer (GC). The primary outcome was the 
overall survival rate. Secondary outcomes were the 
site of the primary tumor, extension of node dissection 
according to Japanese Gastric Cancer Association 
(JGCA) performed in both arms, disease-specific (DSS) 
and disease-free survival (DFS) rates, clinical and 
pathological response rates and resectability rates after 
perioperative treatment. 
RESULTS
We identified a total of 16 randomized controlled trials 
comparing NAC + S (n  = 1089) with SA (n  = 973) 
published in the period from January 1993 - March 
2017. Only 6 of these studies were well-designed, 
structured trials in which the type of lymph node (LN) 
dissection performed or at least suggested in the trial 
protocol was reported. Two out of three of the RCTs 
with D2 lymphadenectomy performed in almost all 
cases failed to show survival benefit in the NAC arm. In 
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the third RCT, the survival rate was not even reported, 
and the primary end points were the clinical outcomes 
of surgery with and without NAC. In the remaining 
three RCTs, D2 lymph node dissection was performed 
in less than 50% of cases or only recommended in the 
“Study Treatment” protocol without any description in 
the results of the procedure really perfomed. In one of 
the two studies, the benefit of NAC was evident only for 
esophagogastric junction (EGJ) cancers. In the second 
study, there was no overall survival benefit of NAC. 
In the last trial, which documented a survival benefit 
for the NAC arm, the chemotherapy effect was mostly 
evident for EGJ cancer, and more than one-fourth 
of patients did not have a proper stomach cancer. 
Additionally, several patients did not receive resectional 
surgery. Furthermore, the survival rates of international 
reference centers that provide adequate surgery for 
homogeneous stomach cancer patients’ populations are 
even higher than the survival rates reported after NAC 
followed by incomplete surgery.
CONCLUSION
NAC for GC has been rapidly introduced in international 
western guidelines without an evidence-based medicine-
related demonstration of its efficacy for a homogeneous 
population of patients with only stomach tumors sub-
mitted to adequate surgery following JGCA guidelines 
with extended (D2) LN dissection. Additional larger 
sample-size multicentre RCTs comparing the newer 
NAC regimens including molecular therapies followed 
by adequate extended surgery with surgery alone are 
needed.
Key words: Gastric cancer; Neoadjuvant chemotherapy; 
Perioperative chemotherapy; D2 lymphadenectomy; 
randomized control trial
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Neoadjuvant chemotherapy (NAC) for re-
sectable locally advanced gastric cancer has been rapidly 
introduced in international western guidelines without 
an evidence-based medicine-related demonstration 
of its efficacy for a homogeneous population of 
patients with stomach tumors who received adequate 
surgery following Japanese Gastric Cancer Association 
guidelines with an extended (D2) lymph nodes 
dissection. Additional randomized controlled trials 
with a larger sample size comparing the newer NAC 
regimens, including molecular therapies followed by 
adequate extended surgery with surgery alone are 
necessary.
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INTRODUCTION
Gastric cancer (GC) is the third most common cancer-
related cause of death[1]. Worldwide, approximately 1 
million new cases of gastric cancer are diagnosed every 
year[2]. In 2016, nearly 13000 new cases are expected 
to be diagnosed in Italy with 7400 (56.9%) cases in 
males and 5300 (40.7%) cases in females[3].
The main prognostic factors for gastric cancer 
patients who receive radical surgery are the number of 
metastatic lymph nodes (LN) and the LN-ratio (the ratio 
between metastatic LN and LN removed).
The 5-year overall survival for resectable GC is 
approximately 20% to 30% worldwide, but, surprisingly, 
it is 70% in Japan and in other eastern countries, 
where the high incidence of the disease is managed 
with screening programs to find tumors at an earlier 
stage, and patients receive adequate surgery, including 
extended LN dissection (D2 gastrectomy)[4]. 
The therapeutic role of LN dissection has been 
a matter of discussion for a long period. In eastern 
countries, D2 lymphadenectomy has been considered 
the standard procedure for many decades[5-7]. In 
western countries, a more limited LN dissection has been 
performed until the last decade due to the low incidence 
of this tumor and the resulting limited experience 
with this complex and challenging procedure that has 
substantial learning curves[8-10]. 
Nevertheless, at the end of the 90s, the Italian 
Gastric Cancer Study Group (IGCSG) randomized 
controlled trial (RCT) showed that when a D2 lym-
phadenectomy with a pancreas-preserving technique 
is performed in references centers, it is a reproducible 
and safe procedure for the radical treatment of GC in 
western countries as well[11]. 
Later, Dutch and IGCSG trials also documented a 
survival benefit of the extended procedure in patients 
with advanced disease[12,13]. Consequently, the survival 
rates for western reference centers adopting D2 gas-
trectomy as the standard procedure for gastric cancer 
were comparable to the rates reported in Japan and 
Korea. Therefore, in international western guidelines 
for the diagnosis and treatment of gastric cancer, D2 
gastrectomy is currently the recommended surgical 
choice for cases of resectable advanced disease.
Although surgery is the treatment of choice for 
GC, in western countries, prognosis remains poor out-
side reference centers even after curative resection, 
especially for the high rate of recurrence and the 
poor efficacy of adjuvant therapy[14]. Many trials have 
investigated the impact of adjuvant treatment by 
comparing surgery alone with surgery followed by 
adjuvant chemotherapy, but there is no definitive 
evidence of any survival advantage[15].
Moreover, in the western world, one-third of patients 
diagnosed with GC have unresectable diseases[16].
Therefore, in the last decade, a multimodal app-
roach of GC has been suggested with the adoption of 
neoadjuvant (preoperative or perioperative) treatment 
275 January 14, 2018|Volume 24|Issue 2|WJG|www.wjgnet.com
reddavid r et  al. Neoadjuvant chemotherapy for gastric cancer
(NAC). Based on the reason that, at least theoretically, 
this treatment may reduce tumor volume, improve 
the R0 resection rate, and kill micro metastases, NAC 
has been recently introduced in the national guidelines 
of many countries, especially after publication of the 
Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC) and the Federation Nationale 
des Centres de Lutte contre le Cancer (FNCLCC) 
-Federation Francophone de Cancerologie Digestive 
(FFCD) RCTs, without a clear and evidence-based 
medicine (EBM)-related demonstration of a survival 
benefit compared to controlled surgery with proper 
enlarged LN dissection in patients with only stomach 
tumors[15,17,18].
Effectively the MAGIC and FNCLCC-FFCD RCTs 
have shown a survival advantage of NAC + surgery vs 
surgery alone, but surgery performed in these patients 
did not include a proper extended lymphadenectomy 
in the majority of cases, and many patients had lower 
esophagus (LE) or esophagogastric junction (EGJ) 
cancer instead of only GC. Therefore, it is possible 
that a proper radical surgery (gastrectomy with D2 
LN dissection) may nullify the survival benefit of NAC 
described after incomplete surgery and also that 
the location of the tumor outside the stomach (EGJ 
and LE), may amplify the response to preoperative 
treatment.
To document a possible benefit of NAC after 
adequate D2 gastrectomy for only stomach cancer, 
we proceeded to review the literature on neoadjuvant 
treatment for resectable gastric cancer by mainly 
investigating these variables. 
MATERIALS AND METHODS
Literature search
We proceeded to conduct a complete review of the 
literature with the support of the Federate Library of 
Medicine of Turin. The body of evidence for this review 
was primarily comprised of mature RCT data and 
meta-analyses of RCTs. 
We searched PubMed, Embase, American Society 
of Clinical Oncology (ASCO) and European society of 
Medical Oncology (ESMO) meeting abstracts as well as 
the Cochrane Library by computer for non-randomized 
and randomized works published from 1993 to March 
2017 (Figure 1).
Keywords were matched and included “NAC or 
neoadjuvant chemotherapy or neo-adjuvant chemotherapy 
or neo-adjuvant chemo-therapy or neoadjuvant chemo-
therapy or preoperative chemotherapy or pre-operative 
chemotherapy or preoperative chemo-therapy or pre-
operative chemo-therapy or perioperative chemotherapy 
or peri-operative chemotherapy or peri-operative 
chemo-therapy or perioperative chemo-therapy ”, “GC or 
gastric cancer or stomach cancer or stomach neoplasm or 
gastric neoplasm or gastric adenocarcinoma or stomach 
adenocarcinoma”, and “RCT or randomized controlled 
trial or randomised controlled trial”.
All published trials comparing NAC-containing 
procedures vs no treatment before surgery in patients 
with gastric cancer (or gastric cancer + cardia cancer 
+ lower-esophagus cancer) were included earlier in our 
analysis. Blinding the trial conditions was not necessary. 
There was no language restriction. 
Inclusion criteria
We screened titles and abstracts of all identified 
papers (5957) and included only trials that satisfied 
the following criteria: patient populations with gastric 
cancer (diagnosed and classified according to 6th or 
7th TNM and/or Japanese Gastric Cancer Association) 
without age, gender and racial limitations[19-21]; inter-
vention and a comparative intervention that was 
clearly documented (NAC + surgery -NAC+S versus 
surgery alone -SA) for GC regardless of the detailed 
NAC regimens that were administered, surgical 
techniques performed (type of gastrectomy and LN 
dissection), pathological classification, location and 
stage of the disease. All patients needed to have a 
history of potentially curative surgery. 
NAC could be performed through oral or intra-
venous (Ⅳ), intraperitoneal (IP) and intra-arterial (IA) 
infusion. 
Esophagogastric junction and lower esophagus 
cancer patients were considered only if they were 
enrolled together with proper gastric cancer patients in 
the same study[15,17,18,22]. In these cases, the results of 
tests for heterogeneity effects according to the site of 
the primary tumor were documented when reported 
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Records identified throught
Database research
(n  = 5957)
Records after duplicates or 
irrelevant articles removed
(n  = 202)
Records screened
(n  = 19)
Articles assessed
For eligibility
(n  = 16)
Records removed
(n  = 3)
Full-text articles
(n  = 12)
Abstracts
(n  = 4)
Figure 1  Literature selection flowchart.
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Quality assessment of RCTs 
The quality of the included RCTs was assessed using 
modified Jadad’s scoring system[24] and Cochrane 
reviewers’ handbook 5.0.1 RCT criteria[25]. The asse-
ssment was based on the randomization methods, the 
report of dropout rates, allocation concealment, the use 
of intention-to-treat (ITT) analysis, and losses to follow-
up, the extent to which valid results were depicted. 
Based on these criteria, the studies were divided into 
high quality group (score ≥ 4) and low quality group 
(score < 4) (Table 1). 
RESULTS
Study selection and population
Figure 1 shows the literature trial selection flowchart. 
In brief, 5957 studies were identified from the literature 
search. Out of all these studies, a total of 202 relevant 
papers documenting the results of any comparison 
of NAC + S vs SA for gastric cancer were selected. 
Then, we proceeded to a further selection of 19 papers 
reporting the results of controlled trials that were 
described as randomized in the title, (6 abstracts and 
13 full-text papers). Nevertheless, a more detailed 
examination showed that in 3 of these studies, patient 
allocation had in fact not been conducted randomly[26-28]. 
Therefore, only 16 papers were proper randomized 
controlled trials that fulfilled our research criteria and 
were included in this review. 
These RCTs were published between 1993 and 
2011 with a 24 to 83 mo follow-up period. A total of 
2062 patients was included in the analysis with 1089 
receiving NAC (52.81%) and 973 (47.18%) undergoing 
SA. 
Characteristics of included studies
In Yonemura’s trial[29] (1993), fifty-five patients with far 
advanced gastric cancer (TNM stage IV) were enrolled 
with 29 who received neoadjuvant treatment and 26 
who underwent surgery alone (Table 2). NAC patients 
were treated with a PMUE regimen, a combination of 
cisplatin (CDDP) 75 mg/m2, mitomycin C (MMC) 10 mg/
body, etoposide 150 mg/body, and 400 mg/d UFT. The 
author reported response rates, resectability rates with 
curative intent and a survival rate advantage in the NAC 
group, but, overall, this was not statistically significant. 
Furthermore, the type of lymph node dissection 
performed in both arms was not reported. 
In 1995, Shchepotin et al[30] included 146 GC patients 
in a RCT in which the tumor stage was not specified 
(Table 2). Fifty patients were treated with surgery 
alone, and 96 patients were submitted to NAC. Out 
of these patients, 49 received intravenous (systemic) 
chemotherapy (IVCH) and 47 received super selective 
intra-arterial chemotherapy (IACH). The chemotherapy 
regimen was not mentioned. Only IACH + S showed 
a response rate and a survival rate advantage over 
by the authors.
When results were reported or updated in more 
than one publication, only the most recent paper was 
used. 
At the end of the process, only RCTs were included 
in this review (Figure 1).
Exclusion criteria
We included only GC patients according to the theory 
of site-dependent differences in tumor genomics 
and biology[23]. Therefore, studies recruiting lower-
esophagus and cardia cancers without gastric cancer 
were excluded. Studies including GC and diseases other 
than GC (lower esophageal cancer, esophagogastric 
junction tumor) were also excluded unless analyses 
were conducted separately.
Studies of preoperative radiotherapy or immu-
notherapy were excluded if they were not associated 
with chemotherapy. 
We excluded patients with history of prior treat-
ment before entering the trial as well.
Types of interventions
Any chemotherapy regimen performed before resective 
surgery with or without postoperative adjuvant 
treatment was included and located in the NAC-arm.
For the surgery alone-arm (SA-arm), we enrolled all 
types of gastrectomy and lymphadenectomy that were 
performed (D0, D1, D1plus, D2, D3). 
Studies in which GC was associated with another 
synchronous malignancy or studies containing mul-
tivisceral resections were excluded.
Outcomes of interest and definitions
The primary outcomes were the overall survival rates 
(time from random assignment to the last follow-up 
or death) and/or disease-free survival rates (DFS) 
(time from random assignment to tumor recurrence 
or death) and/or disease-specific survival rates (DSS) 
(time from random assignment to death from disease). 
Secondary outcomes included the perioperative 
response rates, the R0 (margin negative) resection 
rate after perioperative treatment, and OS or DFS or 
DSS according to the type of lymph node dissection 
performed (D1, D2, others) following Japanese Gastric 
Cancer Treatments Guidelines[21]. Preoperative tumor 
stages were all recorded following TNM classification of 
malignant tumors (mostly from the 6th edition[19]).
The objective response to NAC was evaluated 
as either complete response (CR), partial response 
(PR), stable disease (SD) or progressive disease (PD) 
according to the indications of the Japanese Gastric 
Cancer Association[21]. 
Some trials assessed the down-staging effect of 
NAC by separating out patients with negative nodes 
from patients with positive nodes on pathological ex-
aminations after surgery.
reddavid r et  al. Neoadjuvant chemotherapy for gastric cancer
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surgery alone, and this survival benefit was statistically 
significant (p < 0.01). Patient selection and the type of 
lymph node dissection performed were not reported.
The Kang et al[31] trial enrolled 107 patients with 
operable gastric cancer at TNM stages Ⅲ and Ⅳ. Fifty-
four patients received surgery alone and 53 received 
NAC with a PEF regimen followed by surgery. The 
response rate was not specified. The curative resection 
rate was higher in the NAC + S group than in the SA 
group. However, there was no significant difference in 
overall survival between the two arms (p = 0.114). The 
type of lymph node dissection that was performed was 
not reported (Table 2).
Lygidakis et al[32] recruited 58 patients with resectable 
gastric cancer at all stages. Patients were randomly 
assigned to 3 groups. Group A (No. 20) patients received 
preoperative hypoxic upper abdominal chemotherapy 
using mitomycin-C, 5-fluorouracil, leucovorin, and 
farmorubicin combined with adjuvant systemic che-
motherapy; Group B (No 19) patients received preo-
perative hypoxic upper abdominal chemotherapy without 
systemic chemotherapy; and Group C (No 19) patients 
received surgery alone. Improved survival was reported 
by combining hypoxic upper abdominal perfusion NAC 
with surgery compared to surgery alone. Response rate, 
resectability rate and type of LN dissection were not 
documented (Table 2).
Two-hundred-sixty-two patients with resectable GC 
mostly with serosal invasion were treated by Takiguchi et 
al[33] with either SA (239 patients) or NAC (123) between 
May 1993 and May 1998. NAC patients received 5-FU 
(F group, n = 39) until the day before surgery or 5-FU 
combined with CDDP (FP Group, n = 84). NAC with 5-FU 
combined with low-dose CDDP was reported to reduce 
the rate of intraperitoneal positive cytology, increase the 
rate of successful resections and improve OS without 
statistical significance. The extension of the lymph node 
dissection was not described (Table 2).
In 2000, Wang et al[22] published the results of an 
RCT that included sixty patients with gastric cardia 
cancer that were randomly assigned to surgery alone 
(No. 30) or to NAC with 5-FU (No. 30). As Siewert 
Ⅲ cancers are nowdays considered as proper gastric 
cancers, this study was included in the study despite 
our inclusion criteria[34]. The 5-year OS rate was 
improved in the NAC group but this survival benefit was 
not statistically significant. The resectability rate and 
type of node dissection performed in both groups were 
not reported (Table 2).
Kobayashi et al[35] performed a multicenter 
randomized clinical trial by recruiting 171 patients 
with advanced gastric cancer (a more detailed TNM 
tumor stage was not specified). These patients were 
randomized either to NAC with oral 5’-DFUR (No 91) 
followed by surgery and adjuvant therapy with iv MMC 
and oral 5’-FUDR or for surgery alone (No. 80) followed 
by the same adjuvant therapy. This clinical trial failed 
to demonstrate any survival benefit of preoperative 
chemotherapy over surgery alone. Response rate, 
resectability rate and the type of node dissection 
performed in both arms were not documented (Table 2).
In 2004, Hartgrink et al[4] reported the long-term 
results of the Dutch randomized FAMTX trial. In this 
trial, 59 AGC patients were recruited with no further 
details about the stage of the disease. Of these 
patients, 29 were allocated to the FAMTX regimen 
prior to surgery, while 30 patients received surgery 
alone. The resectability rates were equal for both 
groups. A complete or partial response was registered 
in 32% of the FAMTX group. The median survival since 
randomization was 18 mo in the FAMTX group vs 30 mo 
in the SA group (p = 0.17). Therefore, the trial could 
not show a beneficial effect of preoperative FAMTX. The 
standard surgical procedure included a limited (D1) 
lymphadenectomy. The authors concluded that surgery 
alone is the best treatment for operable gastric cancer 
(Table 2).
In 2004, Nio et al[36] published the results of a RCT in 
Table 1  Quality assessment of all the 16 randomized controlled trials found in literature and included in this study
Study Randomization Allocation concealment Blind Withdrawal and dropout Jadad score ITT
Yonemura et al[29], 1993 Adequate Inadequate Adequate Well reported 5 NR
Shchepotin et al[30], 1995 Unclear Unclear Inadequate NR 1 NR
Kang et al[31], 1996 Unclear Unclear Inadequate Well reported 3 NR
Lygidakis et al[32], 1999 Inadequate Unclear Inadequate Well reported 2 NR
Takiguchi et al[33], 2000 Unclear Inadequate inadequate Well reported 2 NR
Wang et al[22], 2000 Unclear Unclear Inadequate Well reported 3 NR
Kobayashi et al[35], 2000 Adequate Adequate Inadequate Well reported 5 NR
Hartgrink et al[4], 2004 Adequate Adequate Inadequate Well reported 5 NR
Nio et al[36], 2004 Inadequate Inadequate Inadequate Well reported 1 NR
Zhao et al[37], 2006 unclear Unclear Inadequate Well reported 3 NR
Cunningham et al[17], 2006 Adequate Adequate Adequate Well reported 7 YES
Schuhmacher et al[15], 2010 Unclear Unclear Unclear Well reported 4 YES
Imano et al[38], 2010 unclear unclear Unclear Well reported 4 NR
Biffi et al[39], 2010 Unclear Unclear Unclear Well reported 4 YES
Qu et al[40], 2010 Adequate Unclear Unclear NR 4 NR
Ychou et al[18], 2011 Adequate Well reported Unclear Well reported 6 YES
NR: Not reported; ITT: Intention-to-treat analysis.
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Table 2  Positive human epidermal growth factor receptor 2 status by immunohistochemistry and/or fluorescence in situ 
hybridization for the patients enrolled in the ToGA trial[10,11,27]
Author
Countries
Year,
Type of 
publication
N° patients
randomization
Site
Stage
Regimen Response rate Resectability rate Survival rate 
(HR; p)
Node dissection 
(D1,D2, others)
Yonemura et al[29] 
Japan
1993
Abstract
55 Tot
29 NAC + S
26 S
GC
IV
PMUE Adv NAC + S Adv NAC + S Adv NAC+S
Rates NR
NR
Shchepotin et al[30] 
Ukraine
1995
Abstract
146 Tot
50 S
49 IVCH + S
47 IACH + S
GC
NR
NR Adv IACH + S Adv IACH + S Adv IACH + S
P < 0.001
NR
Kang et al[31] South 
Korea
1996
Abstract
107 Tot
54 S
53 NAC + S
GC
III/IV
PEF NR Adv NAC + S No difference
P = 0.114
NR
Lygidakis et al[32]
Greece
1999
Paper
59 Tot
19 S
20 NAC + S + 
IVCH
20 NAC + S
GC
All stages
Mitomycin-C 
+ 5-FU + FA + 
Farmorubicin
NR NR Adv
NAC + S + 
IVCH
NR
Takiguchi et al[33]
Japan
2000
Abstract
262 Tot
139 S
123 NAC + S
GC
III/IV
5FU + CDDP Adv NAC + S Adv NAC+S Adv NAC + S
P = 0.0996
NR
Wang et al[22]
China
2000
Paper
60 Tot
30 S
30 NAC + S
EGJ
NR
5FU Adv NAC + S NR Adv NAC + S
P = 0.17
NR
Kobayashi et al[35]
Japan
2000
Paper
171 Tot
80 S
91 NAC + S
AGC FUDR NR NR Adv S
P = 0.010
NR
Hartgrink et al[4]
The Netherlands
2004
Paper
59 Tot
30 S
29 NAC + S
Proper AGC 
(not EGC)
FAMTX 32% CR or PR EQUAL Adv S
34% S vs
21% NAC + S
P = 0.017
At least 15 nodes
Nio et al[36]
Japan
2004
Paper
295 Tot
193 S
102 NAC + S
GC
All stages
> 50% stage I
UFT NR NR Overall
No Adv. NAC 
+ S
P = 0.6878
stage II/III 
-pN + 
Adv. NAC + S
P = 0.0486
D2
48% S
56% NAC + S
Zhao et al[37]
China
2006
Paper
60 Tot
20 5’-DFUR
20 5FU + CF
20 S
GC
All stages
5’-DFUR
Or
5FU+CF
5’-DFUR and 
5FU + CF 
increase AI 
and reduce PI
NR NR NR
Cunningham et al[17]
United Kingdom
2006
Paper
503 Tot
250 S
253 NAC + S
GC, EGJ, LE
All stages
Epirubicin
Cisplatinum
5-FU
Diameter 5 cm 
vs 3 cm
 P < 0.001
T1 + T2 stages 
> NAC + S
 P = 0.002
NR Adv NAC + S
OS/DFS
23% S
36.3%/
NAC+S
HR 0.75/0.66
P = 
0.009/0.001
more evident 
for EGJ
D2
40% S
42% NAC + S
Schumacher et al[15]
Germany
2010
Paper
282/144 Tot
72 S
72 NAC + S
GC, EGJ 
(Siewert II, III)
stages
III, IV
Cisplatinum + 
FF
Adv in S 
Tumor length, 
thickness and 
width and
P Stages more
R0
67% S
81.9% NAC + S
P = 0.036
LN +
76.5% S
61.4% NAC + S
P = 0.018
No Adv NAC 
+ S 52 ms S
64 ms NAC + 
S
HR = 0.84
P = 0.46
D2 94%
92.6% S
95.7% NAC + S
Imano et al[38]
Japan
2010
Paper
63 Tot
16 S
15 CDDP
16 5-FU
16 5-FU + CDDP
GC
NR
5FU or
CDDP or
5F +CDDP
5-FU + CDDP 
Increases AI
Reduces PI
NR No differences 
in 4 arms
D2 in all arms
Biffi et al[39]
Italy
2010
Paper
240/70 Tot
35 S
34 NAC + S
EGJ (Siewert 
II, III), AG
TCF 65% CR + PR Adv NAC + S
(P value NR)
not evaluated
premature
interruption 
for low accrual
D2 in almost
all cases
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which 295 patients with GC of all stages were included 
(more than 50% were stage I). Overall, 193 patients 
were randomly allocated to the SA-arm and 102 were 
allocated to the NAC-arm with the UFT regimen (Tegafur 
+ 5-FU). The response rate to NAC was 33.3%. The 
resectability rate was not reported. There were no 
significant differences in the OS rates between the NAC 
and SA groups. A survival benefit of NAC over SA was 
documented only in stages 2 and 3 and was higher 
in stage 2 and 3 patients with a complete or partial 
response to NAC compared to non-responders. The 
type of LN dissection performed was D2 only in 48% in 
the SA arm and 56% in the NAC-arm.
Zhao et al[37] studied the apoptosis induced by 
preoperative oral 5’-FUDR administration in GC and 
its mechanism of action. Sixty patients with gastric 
cancer of all TNM stages were randomly assigned to 
3 groups (20 each group) before surgery. Group one 
patients received a NAC treatment with 5’-DFUR oral 
administration; group two patients received 5-FU + 
CF by venous drip for 3-5 d; and group three patients 
received surgery alone. The authors documented a 
significant increase in the apoptosis of gastric carcinoma 
cells and a decrease in the tumor cell proliferation index 
in group one patients after oral 5’-FUDR administration 
compared to groups 2 and 3. Nevertheless, preoperative 
NAC did not improve patient prognosis. The resectability 
rate and type of lymph node dissection were not 
reported.
In the most known RCT on NAC (MAGIC Trial) 
published in 2006 in the New England Journal of 
Medicine (NEJM), Cunningham et al[17] studied the effects 
of preoperative treatment on 503 recruited patients with 
all stages of resectable adenocarcinoma of the stomach, 
esophagogastric junction, or the lower esophagus 
(Table 2). Patients were randomly assigned to either 
a perioperative treatment (250 patients) followed by 
surgery or surgery alone (253 patients). Perioperative 
chemotherapy consisted of three preoperative and 
three postoperative cycles of i.v. epirubicin (50 mg/
m2) and cisplatin (60 mg/m2) on day 1 as well as a 
continuous i.v. infusion of fluorouracil (200 mg/m2 per 
day) for 21 d. The resected tumors were significantly 
smaller and less advanced in the perioperative-
chemotherapy group (p < 0.001), and among patients 
undergoing resection, there was a greater proportion 
of stage T1 and T2 tumors in the perioperative-
chemotherapy arm compared to the surgery alone arm 
(p = 0.002). Compared with the surgery alone arm, the 
perioperative chemotherapy arm had a higher likelihood 
of overall survival (hazard ratio for death, 0.75; 95 
percent confidence interval, 0.60 to 0.93; p = 0.009; 
five-year survival rate, 36% vs 23%) and progression-
free survival (hazard ratio for progression, 0.66; 95 
percent confidence interval, 0.53 to 0.81; p < 0.001). 
Nevertheless, the tumor was located in the stomach 
in 74% of cases in the NAC- arm and 73.9% in the 
surgery alone-arm; the tumor originated from the lower 
esophagus or from the esophago-gastric junction in the 
ramaining cases. D2 lymphadenectomy was performed 
only in 40% of patients in the SA arm and in 42% of 
patients in the NAC arm. Furthermore, according to 
tests for heterogeneity of the treatment effects related 
to the baseline characteristics of patients, the survival 
benefit of perioperative chemotherapy was stronger for 
the esophagogastric junction and the lower esophagus 
site of the primary tumor compared to the proper sto-
mach site. Resectability rates were not significantly 
different among the two groups. 
Schuhmacher et al[15] in 2010 reported the 
preliminary results of the European Organisation 
for Research and Treatment of Cancer ( EORTC) 
randomized trial Nr. 40954 that compared NAC to SA 
for locally advanced cancer of the GC and EGJ (Table 
2). The original trial design required that 360 patients 
with locally advanced (UICC stages Ⅲ and Ⅳ cM0) 
adenocarcinoma of the stomach or esophagogastric 
junction (Sievert Ⅱ and Ⅲ) were randomly assigned to 
Qu et al[40]
China
2010
Paper
78 Tot
39 S
39 NAC + S
AGC Paclitaxel and 
FOLFOX4
Adv NAC + S
P = 0.001
Adv NAC + S
P = 0.025
Adv NAC+S
P = 0.006 at 2 yr
NR
Ychou et al[18]
France
2011
Paper
224 Tot
111 S
113 NAC + S
LE,EGJ,GC
All stages
CDDP + 5FU Adv NAC + S
P = 0.054
Adv NAC + S
P = 0.04
OS (NAC + 
S/S) = 38/24
HR = 0.69
P = 0.02
DFS (NAC + 
S/S) = 34/19
HR= 0.65
P = 0.003
more evident 
for EGJ
D2 
recommended
No data on the
effect of D2 
vs other LN 
dissection
GC: Gastric cancer; NAC: Neoadjuvant chemotherapy; S: Surgery; EGC: Early gastric cancer; AGC: Advanced gastric cancer; EGJ: Esophagogastric junction; 
LE: Lower esophagus; OS: Overall survival; DFS: Disease free survival; LN: Lymph node; D2: D2 lymphadenectomy; FA: Folinic acid; CR: Complete 
response; PR: Partial response; 5-FU: 5-fluorouracil; PMUE: Cisplatin + mitomycin C + etoposide +1-(2-tetrahydrofuryl)- + uracil; IVCH: Intravenous 
(systemic) chemotherapy; IACH: Super selective intra-arterial chemotherapy; PEF: Low dose cisplatinum + epirubicin + 5-fluorouracil; CDDP: Low dose 
cisplatinum; 5'-DFUR: 5'-deoxy-5-fluorouridine; FAMTX: 5-fluorouracil + doxorubicin + methotrexate; UFT: Tegafur + 5-fluorouracil; FF: d-L-folinic 
acid+fluouracile; TCF: Docetaxel + cisplatin + fluorouracil; FOLFOX4: 5-fluorouracil + leucovorin + oxaliplatin; Adv: Advantage; NR: Not reported; Tot: 
Total; AI: Apoptosis index; PI: Cell proliferation index; HR: Hazard ratio.
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preoperative chemotherapy with cisplatin, d-L-folinic 
acid and fluorouracil after surgery or surgery alone. This 
trial was stopped for poor accrual after 144 patients 
were enrolled, including 72 patients in the surgery 
alone arm and 72 in the perioperative-chemotherapy 
treatment arm. More than half of patients had tumors 
located in the proximal third of the stomach, including 
EGJ Siewert type Ⅱ and Ⅲ. The trial showed a 
significantly increased R0 resection and pN0 rates in 
the NAC arm (p = 0.036) compared to the SA arm, but 
failed to demonstrate a survival benefit of perioperative 
treatment. In this trial, adequate surgery with D2 
lymph node dissection was performed in 92.6% of SA 
arm patients and in 95.7% of NAC + S arm patients. 
The survival rates at 2 years were 72.7% (95%CI: 
60.7%-81.7%) and 69.9% (95%CI: 57.7%-79.2%) in 
the neoadjuvant and surgery-only arms, respectively. 
The better outcome than expected after surgery alone 
was ascribed to the high quality of surgery and nodal 
dissection that was performed.
Imano et al[38] in 2010 reported the results of a four-
arm randomized trial designed to evaluate the effects 
of short-term NAC (chemotherapy performed for 72 
h before surgery) on the proliferative ability of cancer 
cells in gastric cancer. Sixty-three patients with gastric 
cancer were randomly assigned to 4 groups as follows: 
Group F, which had a single administration of 5-FU (16 
patients); Group C, which had a single administration 
of CDDP (15 patients); Group FC, which had admini-
stration of both 5-FU and CDDP; and the Control 
Group, which had surgery alone (16 patients). Gastric 
cancer TNM or UICC stages were not reported. The D2 
lymph node dissection was performed in all patients.
The authors found that the combination of CDDP and 
5-FU reduced proliferative ability and increased cellular 
apoptosis in gastric cancer cells. Nevertheless, there 
were no differences in overall survival rates between 
each group. Resectability and R0 resection rates were 
not reported (Table 2). 
A group from the European Institute of Oncology in 
Milan[39] published the data of a multicenter RCT in which 
the objective was the non-inferiority of preoperative NAC 
with TCF regimen followed by surgery (Arm A) compared 
to surgery followed by the same chemotherapy regimen 
(Arm B) on clinical outcomes (morbidity and mortality 
of surgery) in GC patients (Table 2). Based on the initial 
design, a target sample size of 240 patients with locally 
advanced GC was required. Nevertheless, this trial was 
prematurely stopped at 69 randomized patients due 
to insufficient accrual with 34 in Arm A and 35 in Arm 
B, D2 lymphadenectomy was performed in almost all 
cases in both arms. The resectability rate was greater 
in the Arm A compared to the Arm B. In conclusion, 
preoperative TCF was safe and had similar morbidity 
compared to surgery followed by a TCF regimen. 
Furthermore, due to its early discontinuation for slow 
accrual, this study did not provide information about 
the efficacy of preoperative TCF, and no survival results 
were reported. 
Qu et al[40] enrolled 78 patients with cTNM stage Ⅲ 
or Ⅳ (M0) gastric cancer (Table 2). Thirty-nine of these 
patients were randomized to the NAC arm (paclitaxel 
combined with FOLFOX4 regimen) and 39 to the 
surgical arm. The clinical response rate was 66% in 
the NAC arm. The R0 resection rate was significantly 
higher, and the number of lymph node metastases was 
significantly lower in the NAC arm compared to the SA 
arm. In addition, the 2-year survival rate was higher in 
NAC- than in the surgery alone-arm. The location of the 
disease and type of lymph node dissection performed 
were not described. The sample size was very small. 
The results of the FNCLCC and FFCD multicenter 
Phase Ⅲ trial[18] were published in the Journal of 
Clinical Oncology in 2011 (Table 2). In this trial, 224 
patients with resectable adenocarcinoma of the lower 
esophagus, gastroesophageal junction (EGJ), or 
stomach were randomly assigned to either perioperative 
chemotherapy with cisplatin and a fluorouracil regimen 
(NAC arm, n = 113) followed by surgery or surgery 
alone (SA arm, n=111). The curative resection rate was 
significantly higher in the NAC arm compared to that in 
the SA arm (84% vs 73%, p = 0.04). A non-significant 
decrease of lymph node metastases in the NAC arm 
compared to that of the SA arm was reported (67% vs 
80%; p = 0.54). Compared to the SA group, the NAC 
group showed a better OS (5-year rate 38% vs 24%; 
HR for death 0.69; p = 0.02) and a better disease-
free survival (5-year rate: 34% vs 19%; HR for death 
0.65; p = 0.003). Nevertheless, in this trial, only 25% 
of patients had a tumor located in the stomach, while in 
64% of cases, the tumor site was the esophagogastric 
junction, and another 11% of patients had cancer of the 
lower esophagus. While an extended lymphadenectomy 
(D2) was recommended in the “Study Treatment” 
protocol, the lymph node dissections performed in both 
arms were not described in the results. The authors 
concluded that compared to surgery alone, perioperative 
chemotherapy using a combination of cisplatin and 
fluorouracil significantly improved the curative resection 
rate, OS and DFS of patients with adenocarcinoma of 
the lower esophagus, EGJ and stomach. Nevertheless, 
this strong conclusion is an evident contrast to their 
previous comment reported in the “RESULTS” section 
of this paper where they stated that although the 
multivariable analysis showed the two significant 
prognostic factors for OS were the administration of a 
preoperative chemotherapy (p = 0.01) and tumor site 
(p < 0.01), the chemotherapy effect was only significant 
in the esophagogastric junction subgroup, which 
included around two-thirds of the patients. The two 
other subgroups (lower esophagus and stomach) were 
too small to distinguish between no effect and a small 
effect. Should these comments have been emphasized 
in the conclusion of the paper as well? 
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DISCUSSION
Actually, curative resection (R0) with D2 lympha-
denectomy is the recommended standard procedure for 
advanced gastric cancer according to the Japanese[21], 
Korean[41], British[42], German[43], and Italian[44] guide-
lines, as well as the guidelines of the European Society 
for Medical Oncology (ESMO)[45] and the joint ESMO- 
ESSO (European Society of Surgical Oncology) ESTRO 
(European Society of Radiotherapy and Oncology)[46]. 
Recently, the National Comprehensive Cancer Network 
(NCCN) recommended D2 gastrectomy in the United 
States as well[47].
Following the results of the MAGIC[17] and FNCLCC-
FFCD[18] trials, which documented an overall survival 
and a disease free survival benefit after NAC compared 
to surgery alone (from 23% to 36%, p = 0.009 
and from 24% to 38%, p = 0.02, respectively), the 
same reported national and international guidelines 
suggested the adoption of preoperative or perioperative 
chemotherapy, mostly in cases in which lymph node 
metastasis is clinically suspected (cN+) or there is 
a clinical TNM stage 3 or higher ( cT3+). In some 
experiences NAC has been employed for earlier T stage 
as well (cT2+)[47]. 
We deeply believe that the conclusions drawn after 
the publication and circulation of those two trials have 
been too strong in influencing the decision of several 
medical-oncology societies to adopt unconditionally 
preoperative or perioperative chemotherapy regimens 
for locally advanced resectable gastric cancer. We 
have tried to demonstrate that the survival benefits 
reported in MAGIC and FNCLCC-FFCD trials are 
significant in those series, but the 5-year OS rate of 
NAC-arms in both trials is even lower than OS rates 
reported in series from other eastern and western 
reference centers for gastric cancer treatment after only 
adequate curative surgery with extended lymph node 
dissection[48-52]. In fact, these reported benefits come 
from unbalanced series regarding the extent of nodal 
dissection. Furthermore, subsite analysis of both study 
populations clearly shows that chemotherapy effects 
on patient survival claimed in the published reports 
are mostly related to the site of tumor. In both trials, 
the chemotherapy effect is strongly evident in the EGJ 
subgroup.
Consequently, we did a massive literature search to 
investigate the eventual demonstration of any survival 
benefit of preoperative or preoperative chemotherapy 
in patient populations with tumors properly located 
only in the stomach and treated with adequate surgery, 
including complete D2 lymph node dissection as 
described by JGCA guidelines and recommended by 
international guidelines.
In this literature search, we found only 16 rando-
mized controlled trials that compared neoadjuvant 
chemotherapy followed by surgery vs surgery alone in 
gastric cancer. Ten of these 16 papers were low sample-
size single-center trials in which the extension of LN 
dissection was not described at all (Table 2). When 
reported, there was very little evidence of the effects of 
NAC on clinical and pathological responses. Very often, 
the eventual chemotherapy effect on those responses 
was not accomplished by any survival advantage, and in 
cases of survival benefit, this was not significant, or its 
level of significance was decreased by the low sample 
size of the study population. 
Only 6 articles accurately described the extension 
of LN dissection performed on the patient population 
(Table 3).
A proper D2 lymph node dissection was documented 
in only 3 published RCTs[15,38,39]. Two of these trials with 
complete D2 dissection performed in almost all cases 
did not show any survival benefit in the NAC arm[15,38]. 
In the third RCT with adequate surgery and extended 
lymph node dissection, the primary end points were 
morbidity and mortality of surgery. Furthermore, 
due to low accrual with early discontinuation of the 
trial, no information on the efficacy of preoperative 
chemotherapy was provided, and no survival results 
were reported[39]. 
In the remaining 3 RCTs[17,18,36], a proper D2 nodal 
dissection was performed in less than 50% of patients 
or was recommended in the “Study Treatment” protocol 
but not described in the results. 
In one of these trials[18], subsite analysis according 
to the site of the tumor showed that the favourable 
chemotherapy effect on OS reported in the conclusion 
of the trial for all groups of tumor site (lower esophagus, 
EGJ, stomach) was actually strongly evident only for 
EGJ cancers, which represented 64% of all cancers of 
the study population, while the other two subgroups 
(lower esophagus and stomach, 11% and 25%, 
respectively) were too small to distinguish between no 
effect and a small effect. Furthermore, the 5-year OS 
and DFS rates reported in the trial for the SA arm were 
24% and 19%, respectively and were too low compared 
to rates commonly reported in other series from either 
eastern or western reference centers for gastric cancer 
care and research[13,48,50,51,54]. 
In the randomized trial published by Nio et al[36], 
there were no significant differences in overall survival 
rates between the NAC and SA groups in the whole 
study population. A survival benefit of NAC over 
surgery alone was documented only in subsite analysis 
according to the UICC stage of disease. This benefit was 
reported for UICC stage II and III, and it was higher 
in stage II and III patients with complete or partial 
response to NAC compared to non-responders. 
Finally, the MAGIC trial[17] also contains several 
critical points. Despite the reported significant OS 
benefit for the NAC arm, more than one-fourth of 
patients had a cancer located outside the stomach 
(i.e., lower esophagus or esophagogastric junction) 
and D2 lymphadenectomy was performed in only 
40.4% of patients of the SA group and in only 42.5% 
of patients of the perioperative-chemotherapy group. 
Furthermore, non-resectional surgery was performed in 
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16.8 and 13.2% of patients in the SA and NAC groups, 
respectively. As a result of the inadequacy of surgical 
treatment and lymph node dissection administered to 
patients, the rate of overall survival and progression-free 
survival at 5 years after the operation was extremely 
low in the SA group (23% and 18%, respectively), and 
in the NAC group the chemotherapy effect on prognosis 
produced survival rates that remained lower than those 
reported in worldwide reference centers after adequate 
extended surgery without any neoadjuvant treatment. 
Furthermore, although non statistically significant, 
tests for heterogeneity effects according to the site 
of the primary tumor showed that the perioperative 
chemotherapy effect was much more prevalent for 
esophagogastric junction cancer (HR for mortality 0.5) 
and much smaller for stomach cancer (HR for mortality 
0.8). 
Therefore, did preoperative or perioperative che-
motherapy make up for all shortcomings of incomplete 
surgery that did not respect the adequacy of cure 
and extension of nodal dissection? Could neoadjuvant 
treatment be a valid support for inadequate surgery 
alone in those centers where it is performed without a 
complete D2 lymph node dissection? Furthermore, could 
neoadjuvant treatment combined with adequate surgery 
increase survival rates to the rates found by eastern 
authors? 
The only well-designed clinical trials with controlled 
D2 surgery performed in almost all cases in both arms 
were prematurely ended for low accrual[15,39]. One of 
the studies did not even consider survival as a primary 
end point, and the objective of the study was the 
effect of preoperative drugs on clinical outcomes of 
surgery (morbidity and mortality) and on pathological 
response[39]. The EORTC trial effectively aimed to detect 
an improvement in median survival after administration 
of a neoadjuvant treatment, but when it was stopped 
for poor accrual, despite a significant increase in curative 
resection, it failed to demonstrate a survival benefit[15]. 
The authors themselves concluded that the high quality 
of surgery performed with extended resection of re-
gional lymph nodes outside the perigastric area was 
responsible for the better than expected outcome after 
radical surgery alone. In fact, the survival rates at 2 and 
Tab 3  Characteristics and outcomes of randomized controlled trial describing the type of lymph node dissection and the site of 
primary tumor in both arms 
Ref. No. patients 
randomization
Site of primary tumor Node dissection (D1, D2, others) Survival rate (HR, p) HR for site of 
primary tumor
Nio et al[36], 
2004
295 Tot
193 S
102 NAC + S
Stomach D2 in less than 50% overall
48% S 
56% NAC + S
Overall 
No Adv NAC + S
P = 0.6878
stage II/III -pN+
Adv NAC + S 
P = 0.0486
NR
Cunningham 
et al[17], 2006
503 Tot
250 S
253 NAC + S
Stomach 73.9%
EGJ 11.5%
LE 14.6%
D2 in less than 50%
40% S
42% NAC + S 
Adv NAC + S
OS/DFS 5 yr-SR
23%/NR S
36.3%/NR NAC + S
HR = 0.75/0.66
P = 0.009/0.001
HR
LE 0.7
EGJ: 0.5
Stomach: 0.8
Schumacher et 
al[15], 2010
282/144 Tot
72 S
72 NAC + S
Stomach 47.2%
EGJ 52.8% (Siewert II, III)
Proper D2 in 94% overall
92.6% S
95.7% NAC+S
No adv NAC + S
52 ms S
64 ms NAC + S
HR = 0.84 P = 0.46
NR
Imano et al[38], 
2010
63 Tot
16 S
15 CDDP
16 5-FU
16 5-FU + CDDP
Stomach Proper D2 in all patients of both 
arms
No differences for all 
arms
NR
Biffi et al[39], 
2010
240/70 Tot
35 S
34 NAC + S
Stomach 59% 
EGJ 41% (Siewert II, III)
Proper D2 in almost all cases not evaluated
premature
interruption for low 
accrual
NR
Ychou et al[18], 
2011
224 Tot
111 S
113 NAC + S
LE 11%,
EGJ 64%,
Stomach 25% 
D2 recommended
No data on LND performed
OS (NAC + S/S) 38/24
HR = 0.69
P = 0.02
DFS (NAC + S/S) 
34/19
HR = 0.65
P = 0.003
HR 
LE 1.14
EGJ 0.57
Stomach 0.92
 S: Surgery; NAC: Neoadjuvant chemotherapy; Adv: Advantage; LND: Lymph node dissection; OS: Overall survival; DFR: Disease free survival; HR: 
Hazard ratio; LN+: Lymph node positive; D2: D2 lymph node dissection; NR: Not reported; LE: Lower esophagus; EGJ: Esophagogastric junction; pN+: 
Positive lymph nodes at pathological examinations.
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5 years were surprisingly high at approximately 70 and 
50%, respectively, without any differences in the two 
arms of the study.
Survival results after surgery alone in reference centers
As already reported above, several studies from 
either eastern or western countries have reported 
survival rates after adequate surgery with extended 
nodal dissection that were significantly higher than 
rates reported both in the MAGIC[17] and FNCLCC-
FFCD[18] trials after neoadjuvant treatment followed by 
incomplete surgery. Furthermore, these studies consider 
only cancer arising from the stomach, while the two 
RCTs included the lower esophagus and EGJ cancers as 
well (Table 4). 
Recently, Maruyama et al[48] reported an overall 
5-year survival rate of 70.1% among all UICC stages of 
the disease (data from Japanese Nationwide Registry 
of 11.261 gastric patients over the period 1991-2009) 
after surgery alone with accurate D2 lymph node 
dissection. Removing data for Stage Ⅰ patients, which 
usually do not have indications for preoperative treat-
ment, the rates referring to UICC stage Ⅱ and Ⅲ, which 
are commonly submitted to NAC according to the 
current guidelines, were 73% and 44.5, respectively 
and were still significantly higher with respect to figures 
reported in the neoadjuvant settings discussed above 
(Table 4).
In a recent RCT from Taiwan, Wu et al[53] observed an 
overall 5-year survival of 59.5% after extended surgery, 
and the rate of T1 patients in this study population was 
26% (Table 4). 
In 2017, Kim et al[49] published survival data as 
observed in high volume centers in Korea. Overall, 
the 5-year survival was surprisingly very high at 
approximately 80% in all patients, but AJCC stage Ⅰ
represented 63% of the study population. Anyway, the 
5-year survival rates for stage Ⅱ and Ⅲ were still 86.5% 
and 63.7%, respectively (Table 4). 
Survival rates after SA higher than those published 
in MAGIC and FNCLCC-FFCD neoadjuvant settings have 
been reported also in the western world, both in non-
randomized and randomized studies on D2 gastrectomy. 
In historical non-randomized trials published in the 80s 
and 90s in Germany[50], England[51] and Norway[54], the 
5-year OS rates coming from reference centers after 
extended procedures were reported as 46.5, 55% and 
47%, respectively. In all these study populations, T1 
cancers represented less than 10% of all patients (Table 
4). 
In historical randomized trials from Honk-Kong[55] 
and South Africa[56], despite evident limitations due to 
the low accrual, OS after D2 gastrectomy were reported 
as 35% and 67%, respectively (Table 4). 
Table 4  Survival results after surgery alone in reference centers
Study, country Period Setup No. of patients Node dissection 5-yr OS rates
Cunningham et al[17] United Kingdom 1994-2002 MC
RCT
503 D2 in 40% S/42% 
NAC 
NAC + S 36.3%
Surgery alone 23%
Ychou et al[18] France 1995-2003 MC
RCT
224 No data on type 
of LND
NAC + S 38%
Surgery alone 24%
Maruyama et al[48] Japan 1991-2009 MC
Retr
11261 D2 AJCC Stage Ⅱ 73.1%
AJCC stage Ⅲ 44.5%
Wu et al[53] Taiwan 1993-1999 MC
RCT
110/111 D1 vs D3 D1 53.6%/ D3 59.5%
Kim et al[49] South Korea 2009-2011 MC
Retr 
1561 D2 AJCC Stage Ⅱ 86.5%
AJCC Stage Ⅲ 63.7%
Siewert et al[50] Germany 1986-1989 MC
Prosp 
1096 D2 46.60%
Sue-Ling et al[51] United Kingdom 1970-1989 SI
Prosp 
207 D2 55%
Viste et al[54] Norway 1980-1990 SI
Retr 
105 D2 47%
Robertson et al[55] Hong Kong 1987-1991 SI
RCT
25/30 D1 vs D2 D1 45%/D2 35%
Dent et al[56] South Africa 1982-1985 SS
RCT
22/21 D1 vs D2 D1 69%/D2 67%
Bonenkamp et al[57] The Netherlands 1989-1993 MC
RCT
380/331 D1 vs D2 D1/D2: 45%/47%
D2, pT2: 44%
D2, pT3: 22%
D2, LN-/LN+: 69%/30%
Degiuli et al[13] Italy 1998-2006 MC
RCT
133/134 D1 vs D2 D1 /D2: 66.5%/64.2%
D2 pT2-T4: 59%
D2 pT2-pT4 N+: 51%
MC: Multicenter; RCT: Randomized control trial; Retr: Retrospective study; NAC: Neoadjuvant chemoterapy; S: Surgery; Prosp: Prospective study; SI: 
Single institution; SS: Single surgeon; LND: Lymph node dissection; OS: Overall survival; AJCC: American Joint Committee on Cancer; LN+: Lymph node 
positive; LN-: Lymph node negative; D1: D1 lymph node dissection; D2: D2 lymph node dissection; D3: D3 lymph node dissection; NR: Not reported; pT2: 
Pathological TNM T2 stage; pT3: Pathological TNM T3 stage.
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Additionally, in more recent RCTs coming from 
Europe, the Dutch[57] and the IGCSG[13] trials, the rates 
of overall survival observed after proper D2 gastrectomy 
alone were at least comparable to the results reported 
by Cunningham and Ychou in the MAGIC and FNCLCC-
FFCD RCTs after chemotherapy followed by incomplete 
surgery. The results of the Dutch trials were first 
published in the NEJM in 1999. The 5-year OS rate after 
extended nodal dissection was 47% in all patients. It 
was 77%, 44% and 22% in T1, T2 and T3 patients, 
respectively, and 69% and 30% in lymph node-negative 
or lymph node-positive patients, respectively[57] (Table 
4). 
The survival results of the IGCSG RCT were published 
in 2014 in the British Journal of Surgery[13]. The overall 
5-year survival and the 5-year disease-specific survival 
rates were 64.2% and 72.6%, respectively, for the whole 
cohort of patients submitted to D2 lymphadenectomy. 
Tumors were stratified by the depth of invasion and 
by lymph node involvement, and both the OS and 
DSS were calculated for pT2-pT4 patients and for pT2-
pT4 with node-positive patients. In these two subsites 
of patients (which represent a common indication for 
neoadjuvant treatments), the 5-year OS and DSS were 
59% and 69%, respectively. The observed morbidity 
and mortality were extremely low (24% and 2.2%, 
respectively), and therefore, they did not negatively 
impact the effects of extended surgery on survival, in 
contrast to what was described previously by Cuschieri 
et al[58] and Bonenkamp et al[57] in their studies. This 
trial is a clear demonstration that adequate surgery with 
proper extended nodal dissection with low complications 
and mortality can provide impressive survival results 
that are even significantly higher than those reported 
in trials adopting neoadjuvant treatments in a similar 
patient population (Table 4). 
On the other hand, due to the high rates of morbidity 
and mortality, the MAGIC trial designed by Cuschieri 
to demonstrate the superiority of the extended 
gastrectomy over the standard D1 procedure in Great 
Britain failed to document a survival advantage[58,59].
In fact, the OS reported by Cuschieri 5 years after 
surgery was low with 33% in the D2 arm and 35% 
in the D1 arm, which was only comparable to the 
results observed in the MAGIC and FNCLCC-FFCD 
trials when taking all patients into consideration. It 
was even lower if we removed AJCC Stage Ⅰ patients. 
In fact, in the remaining AJCC stage Ⅱ and stage Ⅲ
patients, it was 31% and 11%, respectively. These 
poor survival rates have been related to a combination 
of the observed severe morbidity and mortality with 
the inadequacy of the procedures performed, including 
many protocol violations, especially due to high rates of 
noncompliance (e.g., non-removal of several Ln stations 
that were expected to be removed during lymph node 
dissections). A few years later, the positive results of the 
MAGIC trial on NAC do seem a direct consequence of 
this lack of quality and adequacy of surgical treatment 
provided to gastric cancer patients in many upper 
GI centers from Great Britain until the revolutionary 
centralization of treatments adopted since recent years. 
The chemotherapy effect was more evident when the 
quality of surgery was lower. 
In conclusion, neoadjuvant (preoperative or 
perioperative) chemotherapy for GC has been rapidly 
introduced in international western guidelines without 
evidence-based medicine related demonstrations 
of its efficacy for proper stomach cancer in patients 
who receive a complete extended (D2) lymph node 
dissection. The currently available data support 
the adoption of NAC procedures in several national 
guidelines based on low-volume study populations with 
mixed sites of the primary disease (lower esophagus, 
esophagogastric junction and stomach), and statistical 
tests have often shown evidence of the heterogeneity 
of chemotherapy effects according to the site of the 
primary tumor. In both MAGIC and FNCLCC-FFCD 
trials, tests for heterogeneity showed that perioperative 
chemotherapy effects were much more evident for 
esophagogastric junction cancer and much less for 
stomach cancer. Furthermore, in both these RCTs 
supporting the adoption of NAC, surgery provided 
to patients was incomplete because extended nodal 
dissection was performed in less than 50% of patients 
or not described, and no results on the LN yield were 
documented to warrant its adequacy. The only well-
designed RCT with extended surgery performed in 
almost all cases was prematurely ended for poor 
accrual, but at the moment of its closure, it failed to 
demonstrate a survival benefit for NAC. 
Moreover, in national reference centers for gastric 
cancer care and research, OS and DSS rates of subsites 
of patients theoretically fit for NAC submitted to surgery 
alone with complete D2 dissection and performed for 
cancers located in the stomach only, are even higher 
than those reported after NAC followed by incomplete 
surgery provided to a patient population with mixed 
sites of the primary tumor.
We think additional high volume sample-size 
multicenter (and eventually multinational) RCTs com-
paring newer treatment regimens of neoadjuvant 
settings (capecitabine, oxaliplatin, docetaxel) combined 
with molecular therapies (epidermal growth factor 
receptor inhibitors or antiangiogenic agents) followed 
by controlled D2 surgery with controlled D2 surgery 
alone are necessary to investigate the survival effects 
of modern preoperative chemotherapy in patients with 
only stomach cancer who receive  proper extended 
surgery. 
ARTICLE HIGHLIGHTS 
Research background
Actually, curative surgery with complete D2 lymph node dissection is the 
treatment of choice for gastric cancer (GC). In high-volume reference centers 
surgery alone gives excellent survival rates. Anyway, in western countries, 
 ARTICLE HIGHLIGHTS
reddavid r et  al. Neoadjuvant chemotherapy for gastric cancer
286 January 14, 2018|Volume 24|Issue 2|WJG|www.wjgnet.com
prognosis remains poor outside reference centers even after curative resection, 
especially for the high rate of recurrence mainly due to incomplete nodal 
dissection. Many trials have investigated the impact of adjuvant treatment by 
comparing surgery alone with surgery followed by adjuvant chemotherapy, but 
there is no definitive evidence of any survival advantage.
   Therefore, in the last decade, a multimodal approach of GC has been 
suggested with the adoption of preoperative or perioperative treatment (NAC). 
The problem is that NAC has been introduced in the national guidelines of 
many countries, especially after publication of MRC and French RCTs, without 
a clear and evidence-based medicine (EBM)-related demonstration of a survival 
benefit compared to controlled surgery with proper enlarged LN dissection in 
patients with only stomach tumors.
   In fact, MAGIC and FNCLCC-FFCD RCTs have shown a survival advantage 
of NAC + surgery vs surgery alone, but surgery performed in these patients 
did not include a proper extended lymphadenectomy in the majority of cases, 
and many patients had lower esophageal or cardia cancer instead of only GC. 
Therefore, it is possible that a proper radical surgery (gastrectomy with D2 LN 
dissection) may nullify the survival benefit of NAC described after incomplete 
surgery and also that the location of the tumor outside the stomach (cardia and 
lower esophagus), may amplify the response to preoperative treatment. 
To document a possible benefit of NAC after adequate D2 gastrectomy for 
only stomach cancer, we proceeded to review the literature on neoadjuvant 
treatment for resectable gastric cancer by mainly investigating these variables. 
Research motivation
Neoadjuvant (pre- or peri-operative) chemotherapy has been recently 
introduced in the national guidelines of many countries mainly after publication 
of MRC and French RCTs, without a clear and evidence-based medicine 
(EBM)-related demonstration of a survival benefit compared to controlled 
surgery with proper enlarged LN dissection in patients with only stomach 
tumors. The advantage reported after NAC seems mostly related to incomplete 
nodal dissection performed in both arms of these trials and to heterogeneous 
recruitment of lower esophagus and esophago-gastric junction cancer together 
with proper stomach cancer. Are there any trials among RCTs available in 
Literature investigating the effect of NAC over an homogeneous population 
of patients with only-stomach cancer treated with complete D2 lymph node 
dissection in both arms? Otherwise we could not exclude that: 1) a proper 
radical surgery (gastrectomy with D2 LN dissection) may nullify the survival 
benefit of NAC described after incomplete surgery and 2) the location of the 
tumor outside the stomach (esophago-gastric junction and lower esophagus) 
may amplify the response to preoperative treatment. In other words, NAC 
could be unuseful in proper gastric cancer submitted to curative complete D2 
dissection. 
Research objectives
The main objective was to investigate whether a possible survival benefit 
(OS and/or DSS and/or DFS) of NAC after adequate D2 gastrectomy for only 
stomach cancer was documented in all RCTS available in Literature till now. 
Secondary outcomes included the perioperative response rates, the R0 (margin 
negative) resection rate, and OS or DFS or DSS according to the type of lymph 
node dissection performed (D1, D2, others) after neoadjuvant treatment. We 
realized that no RCTs available till now could document a survival benefit of 
NAC over surgery alone for homogeneous population of patients with tumor of 
the only stomach treated with complete D2 gastrectomy and that a further large 
volume randomized trial is needed.
Research methods
We proceeded to conduct a complete review of the literature with the support 
of the Federate Library of Medicine of Turin. The body of evidence for this 
review was primarily comprised of mature randomized controlled trial (RCT) 
data. All published randomized trials comparing NAC-containing procedures vs 
no treatment before surgery in patients with gastric cancer (or gastric cancer 
+ cardia cancer + lower-esophagus cancer) were included in our analysis. 
Blinding the trial conditions was not necessary. There was no language 
restriction. Esophagogastric junction and lower esophageal cancer patients 
were considered only if they were enrolled together with proper gastric cancer 
patients in the same study. The reason for considering also esophago-gastric 
junction and lower esophageal cancers in the recruitment process was that 
these locations represented a consistent part of the study population of the 
main RCTs actually claimed to be the basis for NAC treatment in gastric cancer. 
At the end of the process, only RCTs were included in this review. As we wanted 
to include all RCTS available in Literature at the moment, any chemotherapy 
regimen performed before resective surgery with or without postoperative 
adjuvant treatment was included and located in the NAC-arm as well as in 
the surgery alone-arm (SA-arm) we enrolled all types of gastrectomy and 
lymphadenectomy that were performed (D0, D1, D1plus, D2, D3). The quality 
of the included RCTs was assessed usin nodified JADAD’s scoring system and 
Cochrane reviewers’ andbook 5.0.1 RCT criteria.
Research results
The currently available data support the adoption of NAC procedures in several 
national guidelines based on low-volume study populations with mixed sites 
of the primary disease (lower esophagus, esophago-gastric junction and 
stomach). Statistical tests have often shown evidence of the heterogeneity 
of chemotherapy effects according to the site of the primary tumor. In fact, in 
both Magic and FNCLCC-FFCD trials, tests for heterogeneity showed that 
perioperative chemotherapy effects were much more evident for esophago-
gastric junction cancer and much less for stomach cancer.
   Furthermore, in both these RCTs supporting the adoption of NAC, surgery 
provided to patients was incomplete because extended nodal dissection was 
performed in less than 50% of patients or not described, and no results on the 
LN yield were documented to warrant its adequacy. The only well-designed 
RCT with extended surgery performed in almost all cases was prematurely 
ended for poor accrual, but at the moment of its closure, it failed to demonstrate 
a survival benefit for NAC.
   Moreover, in national reference centers for gastric cancer care and research, 
OS and DSS rates of subsites of patients theoretically fit for NAC submitted to 
surgery alone with complete D2 dissection and performed for cancers located 
in the stomach only, are even higher than those reported after NAC followed 
by incomplete surgery provided to a patient population with mixed sites of the 
primary tumor.
Research conclusions
This study documented that the adoption of NAC procedures in several national 
guidelines is actually based on low-volume study populations with mixed 
sites of the primary disease (lower esophagus, esophago-gastric junction 
and stomach) and with inadequate surgery as concern the extent of nodal 
dissection (incomplete D2 dissection). In fact, statistical tests reported in these 
trials have shown evidence of the heterogeneity of chemotherapy effects 
according to the site of the primary tumor, documented a major effect mainly 
over esophagogastric junction cancer. Moreover, survival rates reported in 
Surgery-Alone arm by main RCTs claimed to be fundamental for supporting 
the adoption of NAC ( MRC and French trials) are really too low as compared 
to rates documented in reference centers study population after proper D2 
gastrectomy without preoperative chemotherapy. Effectively, in these surgical 
series coming from high volume referral centres, survival rates after extended 
surgery without NAC are even higher than those reported after NAC followed 
by incomplete  surgery.
   Our hypothesis is that, with current data available it ‘s not possible to exclude 
that: (1) The location of the tumor outside the stomach (esophago-gastric 
junction and lower esophagus) may amplify the response to preoperative 
treatment. (2) A proper radical surgery (gastrectomy with D2 LN dissection) may 
nullify the survival benefit of NAC described after incomplete surgery. (3) On 
the contrary, NAC effect on survival is more likely to be evident after incomplete 
surgery. In other words, NAC could be unuseful in cancer of the only stomach 
submitted to curative complete D2 dissection. 
Research perspectives
We think additional high volume sample-size multicenter (and eventually 
multinational) RCTs comparing newer treatment regimens of neoadjuvant 
settings (capecitabine, oxaliplatin, docetaxel) combined with molecular therapies 
(epidermal growth factor receptor inhibitors or antiangiogenic agents) followed 
by controlled D2 surgery with controlled D2 surgery alone are necessary 
to investigate the survival effects of modern preoperative chemotherapy in 
patients with gastric cancer only who receive proper extended surgery. This is 
the ony way to investigate if neoadjuvant therapy can positively impact survival 
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also in homogeneous population of gastric cancer patients without any biases 
related to location of the tumor and adequacy of surgery administered.
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